Dermapharm Holding SE (FRA:DMP)
37.45
+0.25 (0.67%)
At close: Dec 1, 2025
Dermapharm Holding SE Revenue
Dermapharm Holding SE had revenue of 297.73M EUR in the quarter ending September 30, 2025, a decrease of -5.35%. This brings the company's revenue in the last twelve months to 1.17B, up 0.02% year-over-year. In the year 2024, Dermapharm Holding SE had annual revenue of 1.20B with 3.89% growth.
Revenue (ttm)
1.17B
Revenue Growth
+0.02%
P/S Ratio
1.70
Revenue / Employee
325.25K
Employees
3,610
Market Cap
1.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.20B | 44.72M | 3.89% |
| Dec 31, 2023 | 1.15B | 110.19M | 10.59% |
| Dec 31, 2022 | 1.04B | 80.46M | 8.38% |
| Dec 31, 2021 | 960.09M | 151.78M | 18.78% |
| Dec 31, 2020 | 808.31M | 93.94M | 13.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Dermapharm Holding SE News
- 26 days ago - EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 4 weeks ago - EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy - Wallstreet:Online
- 3 months ago - Dermapharm's Steady Growth: H1 Stability & Q2 EBITDA Boost - Wallstreet:Online
- 3 months ago - EQS-News: Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter - Wallstreet:Online
- 3 months ago - EQS-AFR: Dermapharm Holding SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 4 months ago - Dermapharm Holding SE: On Track for Growth in Q2 2025! - Wallstreet:Online
- 4 months ago - EQS-News: Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 - Wallstreet:Online
- 5 months ago - EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy - Wallstreet:Online